Find a Provider

Stephen M. Keefe, MD

Stephen M. Keefe, MD Physician

Adjunct Assistant Professor of Medicine

Dr. Keefe is a private practice physician who is not employed by Penn Medicine.

Clinical Specialties


  • Medicine
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bladder Cancer
    • Kidney Cancer
    • Penile Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Urethral Cancer

Board Certification:

  • Internal Medicine, 2007
  • Medical Oncology, 2010

Conditions & Treatments:

  • bladder (urothelial) cancer
  • clinical trials
  • developmental therapeutics
  • paraganglioma and pheochromocytoma
  • Prostate Cancer
  • renal cell cancer

Practice Locations and Appointments

  • Genito-urinary Oncology

    Abramson Cancer Center Perelman Center for Advanced Medicine, West Pavilion, 4th Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: University of Chicago School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Society of Clinical Oncology (ASCO), International Eastern Cooperative Oncology Group (ECOG), International


Dr. Keefe is a private practice physician who is not employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.


Selected Publications:

Mamtani R, Pfanzelter N, Haynes K, Finkelman BS, Wang X, Keefe SM, Haas NB, Vaughn DJ, Lewis JD: Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas Diabetes Care 37 (7): 1910-7,2014.

Ju M, Kao GD, Steinmetz D, Chandrasekaran S, Keefe SM, Guzzo TJ, Christodouleas JP, Hahn SM, Dorsey JF: Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study Cancer Biology and Therapeutics 15 (6): 683-7,2014.

Keefe SM, Hennessy M, Gunnarsson O, Mamtani R, Vaughn D, Hoffman-Censits Jean, Nathanson KL, Lal P, Pryma D, Eliasof S, Garmey E, Cohen RB, Haas NB: Phase 1b/2a study of the nanopharmaceutical CRLX101 with bevacizumab in refractory metastatic renal cell carcinoma - results from the planned interim analysis American Association of Cancer Research (AACR) 2014 Annual Meeting : 2014.

Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn DJ, Keefe SM, Guzzo T, Malkowicz SB, Christodouleas JP: Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation International Journal of Radiation Oncology, Biology and Physics 88 (3): 2014.

Brose MS, Frenette CT, Keefe SM, Stein SM: Management of sorafenib-related adverse events: a clinician's perspective Seminars in Oncology Suppl 2 : S1-S16,2014.

Keefe SM, Heitjan D, Hennessey M, Robinson J, Mykulowicz K, Marshall A, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Lal P, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB: Interim Results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 (Cerulean Pharma, Inc., Cambridge, MA, USA) with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC) 2014 GU Cancers Symposium ASCO Supplement : 2014.

Keefe SM, Rosen MA, Robinson J, McGibney K, Marshall A, Mamtani R, Vaughn DJ, O'Dwyer PJ, Haas NB, Pryma DA: Results of a feasibility study of I-124 girentuximab (Wilex AB) in metastatic clear cell renal cell carcinoma (m ccRCC) 2014 GU Cancers Symposium ASCO Supplement : 2014.

Keefe SM, Nathanson KL, Rathmell WK: Molecular biology of renal cell carcinoma Seminars in Oncology 40 (4): 421-8,2013.

Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ: Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy BJU Int 112 (1): 13-25,2013.

Keefe SM, Cohen R, Eliasof S, Garmey EG, Mykulowicz KM, Pryma D, Haas NB: A Phase Ib-IIa Study Evaluating the Nanopharmaceutical CRLX101 in Combination with Bevacizumab in the Treatment of Patients with Advanced Renal Cell Carcinoma (NCT01625936) 2013 Association of American Cancer Research : 2013.

Academic Contact Info

Merck Research Laboratories
126 E. Lincoln Avenue
Rahway, NJ 07065

Philadelphia, PA 19104
Patient appointments: 800-789-PENN (7366)

Related Links